86 Preliminary results of a stage oriented multimodality treatment including surgery for selected subgroups of limited disease small cell lung cancer (SCLC)
Wilfried Eberhardt(National Center for Tumor Diseases), S. Seeber, Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), L. Schlenger(Charité - Universitätsmedizin Berlin), H. Wilke(Kliniken Essen-Mitte), A. Haarstrik(Essen University Hospital), U. Fuths(Essen University Hospital), D. Greschuhna(Essen University Hospital), Martin Stuschke(Essen University Hospital), M.R. Nowrouslen(Essen University Hospital), Mark Müller, U. Klaassen(West German Heart and Vascular Center Essen), Georgios Stamatis(Ruhrlandklinik), S. Kolks(University of Duisburg-Essen), N Konietzko
Cited by 0
Related Papers
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
|Journal of Clinical Oncology|2017|872
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
|The Lancet Oncology|2011|574